[go: up one dir, main page]

WO2014194267A3 - Wnt peptide pharmacophore compositions and methods of use thereof - Google Patents

Wnt peptide pharmacophore compositions and methods of use thereof Download PDF

Info

Publication number
WO2014194267A3
WO2014194267A3 PCT/US2014/040352 US2014040352W WO2014194267A3 WO 2014194267 A3 WO2014194267 A3 WO 2014194267A3 US 2014040352 W US2014040352 W US 2014040352W WO 2014194267 A3 WO2014194267 A3 WO 2014194267A3
Authority
WO
WIPO (PCT)
Prior art keywords
wnt
compositions
methods
expresses
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2014/040352
Other languages
French (fr)
Other versions
WO2014194267A2 (en
Inventor
Kenan Christopher GARCIA
Claudia Yvonne JANDA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of WO2014194267A2 publication Critical patent/WO2014194267A2/en
Publication of WO2014194267A3 publication Critical patent/WO2014194267A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Wnt compositions and methods for their use are provided. Compositions of the invention comprise fragments of wnt polypeptides having a desired biological activity, which fragments are referred to herein as "wnt peptide pharmacophores". These compositions and methods find particular use in determining binding to Wnt receptors; inhibiting Wnt signaling in a cell that expresses a Wnt receptor; in delivering a functional moiety to a cell that expresses a Wnt receptor; and as an immunogen for producing Wnt-specific antibodies.
PCT/US2014/040352 2013-05-30 2014-05-30 Wnt peptide pharmacophore compositions and methods of use thereof Ceased WO2014194267A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361829133P 2013-05-30 2013-05-30
US61/829,133 2013-05-30

Publications (2)

Publication Number Publication Date
WO2014194267A2 WO2014194267A2 (en) 2014-12-04
WO2014194267A3 true WO2014194267A3 (en) 2015-02-26

Family

ID=51989543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/040352 Ceased WO2014194267A2 (en) 2013-05-30 2014-05-30 Wnt peptide pharmacophore compositions and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2014194267A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7385575B2 (en) * 2017-10-09 2023-11-22 バイオ－テクネ コーポレーション WNT/SFRP complexes, WNT-containing compositions, WNT-expressing cells, and methods of producing, purifying, and using them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100199362A1 (en) * 2007-04-26 2010-08-05 President And Fellows Of Harvard College Wnt ligands involved in blood-brain barrier development and uses therefor
WO2012004291A1 (en) * 2010-07-06 2012-01-12 Nanologica Ab Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients.
WO2012103360A2 (en) * 2011-01-28 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods of use thereof
US20130022613A1 (en) * 2002-06-14 2013-01-24 Robb Krumlauf Wise/sost nucleic acid sequences and amino acid sequences

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130022613A1 (en) * 2002-06-14 2013-01-24 Robb Krumlauf Wise/sost nucleic acid sequences and amino acid sequences
US20100199362A1 (en) * 2007-04-26 2010-08-05 President And Fellows Of Harvard College Wnt ligands involved in blood-brain barrier development and uses therefor
WO2012004291A1 (en) * 2010-07-06 2012-01-12 Nanologica Ab Improved method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmaceutical active ingredients.
WO2012103360A2 (en) * 2011-01-28 2012-08-02 The Board Of Trustees Of The Leland Stanford Junior University Wnt compositions and methods of use thereof

Also Published As

Publication number Publication date
WO2014194267A2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
WO2012103360A3 (en) Wnt compositions and methods of use thereof
IL263268A (en) Antibody for binding to interleukin 4 receptor
MX347515B (en) Frizzled-binding agents and uses thereof.
WO2014145016A3 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
JO3407B1 (en) Tetrahydropyrazolopyrimidines
EA201890866A1 (en) BINDING MOLECULES THAT INHIBIT CANCER GROWTH
WO2012064836A9 (en) Methods and compositions for neural disease immunotherapy
WO2013184912A3 (en) Binding agents that modulate the hippo pathway and uses thereof
LT2563400T (en) MODIFIED BINDING PROTEINS THROUGH VEGF-A RECEPTOR INTERACTION
MX2012003598A (en) Bispecific death receptor agonistic antibodies.
MY162825A (en) Antibodies for epidermal growth factor receptor 3 (her3)
WO2015007536A3 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HUE059811T2 (en) Stabilized preparations containing antibodies against the interleukin-6 receptor (IL-6R).
MX352881B (en) Methods and compounds useful in the synthesis of orexin-2 receptor antagonists.
NZ727701A (en) Platinum compounds, compositions, and uses thereof
BR112013008255A2 (en) isolated antibody or functional fragment thereof, use of an isolated antibody or functional fragment thereof, pharmaceutical composition, polynucleotide, vector, transformed cell, and method for producing antibody
WO2013063458A3 (en) Inhibiting g protein coupled receptor 6 kinase polypeptides
EP2749568A4 (en) POLYPEPTIDE FOR THE PREVENTION OF CELL DNA SYNTHESIS AND FOR THE INHIBITION OF CELL PROLIFERATION AND USE THEREOF
MX2015014198A (en) Antibodies targeting m-csf.
WO2014144095A3 (en) Compositions comprising d-amino acid peptides and methods of production and use thereof for inhibiting autoantibodies
PH12012502300A1 (en) Nicotinic receptor non-competitive antagonists
WO2014194267A3 (en) Wnt peptide pharmacophore compositions and methods of use thereof
WO2015164411A3 (en) Small molecule inhibitors of g protein coupled receptor 6 kinases polypeptides
HK1214279A1 (en) Methods and compositions relating to anti-il-21 receptor antibodies
WO2013067105A3 (en) Nicotinic receptor non-competitive modulators

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14804787

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14804787

Country of ref document: EP

Kind code of ref document: A2